Popular Stories

Gilead's Remdesivir-Like Compound To Be Studied By NIH For Efficacy Against COVID-19

reported Monday.” data-reactid=”19″>The National Institutes Of Health is set to investigate a Gilead Sciences, Inc (NASDAQ: GILD) compound, similar to remdesivir, which could be effective against COVID-19, Stat reported Monday.

Two researchers at the University of Texas MD Anderson Cancer Center have reportedly been arguing that the drugmaker should test the compound for effectiveness against COVID-19. 

The researchers argued that GS-441524 is easier to synthesize compared to remdesivir and thus it should be easier to create higher oral doses.

Gilead claimed earlier that remdesivir is more effective in test tubes and animal models compared with its other compound in stopping viral replication, and is more active in lab tests against many types of coronaviruses including SARS-COV-2, Stat reported.

This month, the California-based drugmaker sought full approval from the Food and Drug Administration for remdesivir, which is approved for emergency use in COVID-19 patients.

View Article Origin Here

Related Articles

Back to top button